EdiGene | Genome Editing for a Better Life

News

08
2021-09

EdiGene Announces Clinical Sites Activation and First Patient Enrolled in Multicenter Phase I Clinical Trial of its Investigational Gene-editing Hematopoietic Stem Cell Therapy ET-01 for Patients with Transfusion Dependent β-thalassemia

LEARN MORE
21
2021-04

EdiGene Raises Approximately USD 62 Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies

LEARN MORE
18
2021-01

EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration

LEARN MORE
14
2020-12

EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan

LEARN MORE
27
2020-10

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

LEARN MORE
13
2020-10

EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage

LEARN MORE
18
2022-11

EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia

LEARN MORE
13
2020-10

Out to pioneer gene editing in China, EdiGene bags $67M to begin clinical testing for β-thalassemia therapy, universal CAR-T

Endpoints - Amber Tong

LEARN MORE
27
2020-05

EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer

LEARN MORE
29
2020-04

EdiGene to Present Data on its Lead RNA Base Editing Program to Treat Patients with the Most Severe Form of MPS I

LEARN MORE

Edit Code of Life,Creating Transformative Solutions for Serious Human Diseases

News